

CELYAD S.A.

FORM 6-K (Report of Foreign Issuer)

Filed 02/20/18 for the Period Ending 02/20/18

Telephone	32 10 394 100
CIK	0001637890
Symbol	CYAD
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of February, 2018

Commission File Number: 001-37452

CELYAD SA

(Translation of registrant's name into English)

**Rue Edouard Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBITS

<u>Exhibit</u>	<u>Description</u>
99.1	Press Release dated February 7, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 20, 2018

CELYAD SA

/s/ Patrick Jeanmart

Patrick Jeanmart
Chief Financial Officer



Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Celyad SA (NYSE Euronext Brussels and NYSE Euronext Paris: CYAD), disclose the information required under article 15, § 1 of the Law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies.

Following the exercise of 4,500 warrants of the Company on 7 February 2018, the share capital is increased to 34,349,014.57 EUR and is represented by 9,872,344 shares.

FIGURES – MODIFIED ON 7 FEBRUARY 2018 FOLLOWING THE EXERCISE OF WARRANTS

New shares issued following the exercise of Company's warrants: 4,500

Company's share capital: 34,349,014.57 EUR.

Total number of shares with voting rights: 9,872,344.

Total number of voting rights (= denominator): 9,872,344

Statutory thresholds – unchanged

Statutory thresholds for participation (article 12 of the by-laws): 5%, 10%, 15%, 20% and so by increments of 5%.

CONTACT PERSON FOR REGULATED INFORMATION (FINANCIAL, TRANSPARENCY)

According to Law, any transparency declaration must be sent to our Company by email to the attention of Patrick Jeanmart, Chief Financial Officer (CFO): pjeanmart@celyad.com.

Further questions about the content of this release can be sent to investors@celyad.com.

***END**